Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03053102

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH) Clinical Trial

Official title:
A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of ACH-0144471 in Untreated Patients With Paroxysmal Nocturnal Hemoglobinuria

Clinical Trial Summary

The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH.

Clinical Trial Description

After 12 weeks of treatment, participants deriving clinical benefit were offered enrollment in a separate long-term extension study (ACH471-103, NCT03181633). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03053102
Study type Interventional
Source Alexion Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date March 31, 2017
Completion date November 14, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT00004143 - Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Phase 2
Terminated NCT05116787 - BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy Phase 2
Recruiting NCT06294301 - A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants Phase 1
Completed NCT03472885 - Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab Phase 2
Completed NCT03946748 - Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Enrolling by invitation NCT03427060 - Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms Phase 2
Completed NCT03078582 - Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Phase 2
Not yet recruiting NCT06312644 - Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Completed NCT03588026 - Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576 Phase 3
Completed NCT03056040 - ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Phase 3
Completed NCT00145613 - Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies Phase 2
Completed NCT00587054 - Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders Phase 2
Recruiting NCT05876312 - Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Phase 1
Completed NCT04820530 - Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy Phase 3
Terminated NCT03225287 - Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study Phase 2
Completed NCT04558918 - Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment Phase 3
Completed NCT02352493 - A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH Phase 1/Phase 2
Recruiting NCT04901936 - A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Completed NCT02264639 - A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH Phase 1
Recruiting NCT03520647 - Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis Phase 2